Novavax Vice President Matthew Rousculp on reactogenicity, vaccine hesitancy, and supporting informed decisions.
ASM/ESCMID
Novavax COVID-19 Vaccine Linked to Fewer Adverse Effects in Health Care Workers and First Responders
At ESCMID Global 2025, SHIELD study data show Novavax recipients experienced fewer adverse effects and missed less work compared with those who received the Pfizer-BioNTech COVID-19 vaccine.
Advertisement
Global study reveals sharp rise in deaths linked to high-risk antibiotic use, prompting urgent calls for stewardship reform and surveillance improvements globally.
Jeff Fischer, MBA, discusses promising preclinical data on a cross-species, cross-strain influenza candidate with pandemic potential at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases.
The PERSEUS study aimed to assess the effectiveness and safety of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin presented at the 34th ESCMID Global conference.
Advertisement
Advertisement
Trending on Contagion Live
1
FDA Approves IV Antbiotic, Contepo, for Complicated Urinary Tract Infections
2
In A Matter of Months, MMR Vaccine Confidence Drops Significantly
3
Listeria Outbreak Update: 27 Illnesses and 6 Deaths Linked to Packaged Meals
4
Clesrovimab Lowers RSV Hospitalizations and Illness in Healthy Infants
5
